Cellectar Biosciences to Report Full Year Financial Results and Host a Conference Call on Wednesday, March 4, 2026
Rhea-AI Summary
Cellectar Biosciences (NASDAQ: CLRB) will report full year financial results for the period ended December 31, 2025, and host a corporate update and conference call on Wednesday, March 4, 2026 at 8:30 a.m. Eastern Time.
The event will be accessible by toll-free dial-in and webcast; a replay of the presentation will be available on the company’s Investor Relations Events page.
Positive
- None.
Negative
- None.
News Market Reaction – CLRB
In the Feb 25 session, CLRB gained 3.57%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Conferences,earnings date Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Nov 06 | Earnings date notice | Neutral | +2.7% | Announced Q3 2025 results date and investor conference call details. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Prior “earnings date/conference call” news on Nov 6, 2025 coincided with a modest +2.69% move, indicating these scheduling updates have previously aligned with a small positive reaction.
Recent news shows CLRB balancing clinical, financial, and corporate milestones. A prior scheduling release on Nov 6, 2025 set expectations for Q3 2025 results and a corporate update, with shares rising 2.69% over the next day. Since then, filings highlighted liquidity constraints, warrant-related financings, and continued advancement of iopofosine I 131. Today’s full-year 2025 call announcement fits this pattern of using conference calls to provide broader strategic and financial updates to the market.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FLORHAM PARK, N.J., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced that the Company will report financial results for the full year ended December 31, 2025, and provide a corporate update on March 4, 2026, at 8:30 a.m. Eastern Time.
| Conference Call & Webcast Details: | |
| Date: | Wednesday, March 4, 2026 |
| Time: | 8:30 am Eastern Time |
| Toll Free: | 1-800-717-1738 |
| Conference ID: Webcast: | 08197 Click HERE |
A replay of the corporate presentation will be available on the Events section of the Company’s Investor Relations website.
About Cellectar Biosciences, Inc.
Cellectar Biosciences is a late-stage clinical radiopharmaceutical company focused on the discovery and development of proprietary drugs for the treatment of cancer. The company’s core objective is to leverage its proprietary Phospholipid Drug Conjugate™ (PDC) delivery platform to develop the next-generation of cancer cell-targeting treatments that deliver improved efficacy and better safety.
The company’s product pipeline includes its lead assets: iopofosine I 131, a PDC designed to provide targeted delivery of iodine-131 (radioisotope) for the treatment of hematologic and solid tumor cancers such as Waldenstrom’s macroglobulinemia (WM) and pediatric high grade gliomas; CLR 121125 (CLR 125), an iodine-125 Auger-emitting program targeting solid tumors, such as triple negative breast, lung and colorectal cancers; CLR 121225 (CLR 225), an actinium-225 based program targeting solid tumors with significant unmet need, such as pancreatic cancer; and proprietary preclinical PDC chemotherapeutic programs and multiple partnered PDC assets.
Iopofosine I 131 has been studied in Phase 2b trials for relapsed or refractory WM and multiple myeloma (MM), non-Hodgkin’s lymphomas and central nervous system (CNS) lymphoma, and the CLOVER-2 Phase 1b study, targeting pediatric patients with high-grade gliomas, for which Cellectar is eligible to receive a Pediatric Review Voucher from the FDA upon approval. The FDA has granted iopofosine I 131 Breakthrough Therapy, six Orphan Drug, five Rare Pediatric Drug and two Fast Track Designations for various cancer indications. The European Medicines Agency (EMA) has also granted iopofosine I 131 PRIME and orphan drug designations for the treatment of WM.
For more information, please visit www.cellectar.com or join the conversation by liking and following us on the company’s social media channels: X, LinkedIn, and Facebook.
Investor Contact:
Anne Marie Fields
Precision AQ
212-362-1200
annemarie.fields@precisionaq.com
